Advertisement

Organisation › Details
Calyxt Inc. (Nasdaq Global Market: CLXT)
![]() |
Start | 2015-05-01 renamed |
Group | Cellectis (Group) | |
Predecessor | Cellectis Plant Sciences Inc. | |
![]() |
Industry | genomic technology |
Industry 2 | transgenic plant | |
![]() |
Person | Blome, James A. (Jim) (Cellectis 201810– CEO of Calyxt Inc before Bayer CropScience LP + Valent + Agrliance) |
Person 2 | Tripodi, Federico A. (Cellectis 201609c– CEO of Calyxt before Monsanto) | |
Street | 600 County Road D W. Suite 8 | |
City | 55112 New Brighton, MN | |
Tel | +1-651-683-2807 | |
Address record changed: 2015-05-12 | ||
Basic data | Employees | n. a. |
Currency | USD | |
Annual sales | 399,000 (revenue (2016) 2016-12-31) | |
Profit | -12,086,000 (2016-12-31) | |
Cash | 3,007,000 (2017-03-31) | |
Record changed: 2019-07-13 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for Cellectis (Group)
- [1] Cellectis S.A.. (10/29/19). "Press Release: First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma". New York, NY....
- [2] Cellectis S.A.. (10/1/19). "Press Release: Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates". Basel & New York, NY....
- [3] Allogene Therapeutics, Inc.. (12/3/18). "Press Release: Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting". South San Francisco,...
- [4] Cellectis S.A.. (9/19/18). "Press Release: CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board". New York, NY....
- [5] Cellectis S.A.. (9/18/18). "Press Release: Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP". Minneapolis, MN & New York, NY....
- [6] Cellectis S.A.. (6/12/18). "Press Release: Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports". New York....
- [7] Calyxt, Inc.. (5/22/18). "Press Release: Calyxt Announces Successful Closing of $60.9 Million Public Offering". Minneapolis, MN....
- [8] Calyxt, Inc.. (5/15/18). "Press Release: Bayer CropScience, LP Agrees to Settle Lawsuit Filed by Calyxt in Delaware Chancery Court". Minneapolis, MN....
- [9] Cellectis S.A.. (5/7/18). "Press Release: Cellectis Reports 1st Quarter 2018 Financial Results". New York, NY....
- [10] Cellectis S.A.. (5/2/18). "Press Release: Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)". New York, NY....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top